
Equitable Access to High-Cost Pharmaceuticals
Description
Key Features
- Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs
- Incorporates existing guidelines and recommendations by international organizations
- Compares and contrasts how different countries fund and police high-cost drug access
- Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing
- Reviews novel pharmaceuticals of current research interest
Readership
Pharmacoeconomics, health economics, pharmacy, public health and health administration professionals. Policymakers and funding bodies. Pharmaceutical research and insurance staff working across pricing, market access, policy and marketing. Some graduate and 1st year PhD students studying pharmacoeconomics, pharmacy and health economics
Table of Contents
1. Access to High Cost Medicines: An Overview
2. Health Technology Assessment
3. High-Cost Medicines in England
4. Managed Entry Agreements and High Cost Medicines (European Perspective)
5. Setting a Public Health Agenda to Support Access to High-Cost Medicines
6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines
7. Access to High Price Medicines in Portugal
8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda
9. Equitable Access to Biosimilars: An Overview
10. Access to High-Cost Medicines in Europe
11. Access to High-Cost Medicines in Australia
12. Access to High-Cost Medicines in New Zealand
13. Access to High-Cost Medicines in Wales
Product details
- No. of pages: 238
- Language: English
- Copyright: © Academic Press 2018
- Published: February 21, 2018
- Imprint: Academic Press
- Paperback ISBN: 9780128119457
- eBook ISBN: 9780128119624
About the Editor
Zaheer-Ud-Din Babar
Affiliations and Expertise
Ratings and Reviews
There are currently no reviews for "Equitable Access to High-Cost Pharmaceuticals"